Insurance programmes for life science companies must address highly specific risks that are not always adequately covered by a standard policy. In this sector, a temperature fluctuation, a biological contamination event, a product defect or a development delay can simultaneously affect operations, the balance sheet and third-party liability. This article reviews the most relevant property and liability coverages for the sector.
What is insurance for life science companies?
Insurance for life science companies refers to insurance programmes specifically designed for pharmaceutical companies, biotechnology firms, laboratories, medical device manufacturers and companies engaged in research and development (R&D) activities. Unlike generic industrial policies, these programmes include coverages tailored to the sector’s specific risks: deterioration of sensitive assets, biological contamination, loss of R&D value, product liability and clinical trials.
Why does insurance for life science companies require a specific approach?
Companies in this sector work with particularly sensitive processes, assets and liabilities. A standard property or liability policy is not designed to cover the operational reality of a company that manufactures medicines, develops biological products or conducts clinical trials. The most relevant risks that distinguish this sector are:
- Preservation of perishable goods and critical materials under controlled conditions of temperature, humidity and sterility.
- R&D projects with high economic value, even when they have no immediate commercial value.
- Exposure to claims arising from defective products, contamination, market withdrawal or damage resulting from clinical trials.
- Financial impact from project interruption or delays in reaching the market (time to market).
- Contractual milestone payments that may be lost if a loss event delays the research programme.
For this reason, insurance for life science companies must include coverages that protect not only tangible assets, but also the future value of the project, business continuity and third-party liability.
Summary of key coverages in insurance for life science companies
| Coverage | Type | Key relevance |
|---|---|---|
| Deterioration of perishable goods | Property | Vaccines, reagents, biological samples |
| Undamaged goods declared unfit for commercialisation | Property | Stock or R&D assets blocked by regulatory authority |
| Delay in commercialisation | Property | Loss of income due to delayed product launch |
| Biological contaminants | Property | Decontamination costs and loss of activity |
| Milestone or phase-based payments | Property | Unrecoverable income due to loss of R&D assets |
| Research and development assets | Property | R&D assets at insured premises and off-site |
| Research or production animals | Property | Loss or damage suffered by animals involved in research |
| Accidental damage during handling | Property | Sensitive materials in internal transit |
| Products and completed operations liability | Liability | Medicines, biologics, medical devices |
| Claims-made basis + retroactive date | Liability | Claims arising long after the triggering event |
| Combination and blending | Liability | APIs, excipients, integrated components |
| Assembly and disassembly costs | Liability | Replacement of defective incorporated components |
| Product recall | Liability | Economic and operational impact of recalls |
| Clinical trials | Liability | Specific exposure from clinical trial activity |
| Accidental pollution and pure financial loss | Liability | Extensions that differentiate from standard policies |
Property coverages in insurance for life science companies
1. Deterioration of perishable goods due to changes in temperature or environmental conditions
In a life science company, a failure in industrial refrigeration, humidity control or other environmental conditions can render vaccines, reagents, cultures, biological samples or finished products unusable — even without a fire or a flood.
This coverage can respond to the costs of repair or replacement when deterioration results from a sudden and accidental change in temperature, humidity or other environmental conditions. Deterioration may include changes in colour, texture, appearance or odour. It is a critical coverage because it protects one of the sector’s most vulnerable points: the physical, chemical or biological integrity of the product.
2. Undamaged goods declared unfit for use or commercialisation
A distinctive feature of this sector is that stock or R&D assets may not have suffered direct physical damage but, following a covered loss, may be rendered unusable or unfit for commercialisation by decision of the competent regulatory authority.
This coverage responds to the depreciation of such goods when an authority declares them unfit for trade or requests in writing that they not be placed on the market. It may include loss of gross profit or fixed expenses due to interruption of activity, as well as disposal, destruction and withdrawal costs.
3. Delay in commercialisation
In life science, reaching the market late can cause an economic loss as significant as losing a tangible asset. The value of a molecule, a device or a product improvement often depends on the timing of launch (time to market).
This coverage protects the effective loss of gross profit or fixed expenses when sudden and accidental physical damage to R&D activities causes a delay in the planned launch of a new product or the improvement of an existing one.
4. Biological contamination
Research or biological manufacturing facilities face specific exposure to contamination events. This coverage can respond to physical damage caused by a real, sudden and accidental release of contaminants, the costs of cleaning and eliminating insured property and R&D assets, and the loss of gross profit or fixed expenses during the indemnity period.
5. Milestone or phase-based payments
Many biotechnology, pharmaceutical or research companies rely on contracts where payments are linked to the achievement of milestones. If a loss event affects R&D assets and delays the project, the financial impact may consist of the loss of those contractually agreed revenues.
This coverage protects contractually unrecoverable amounts, lost or reduced, that the company would have received from third parties had the R&D assets not suffered sudden and accidental physical damage from a covered risk. It reflects clearly that, in this sector, the insurable risk extends beyond the physical asset to the future economic value of the project.
6. Research and development assets
R&D assets have very high strategic value and are complex to replace. It is worth securing specific coverage for research and development assets against sudden and accidental physical loss or damage, both at insured premises and, subject to a sub-limit, away from the premises within the territorial scope of the policy.
7. Research or production animals
When they form an essential part of the insured activity, research or production animals require specific attention. This coverage responds to loss or damage suffered by these animals when they are involved in research, development or production processes, and their absence can create significant exposure for certain companies in the sector.
8. Accidental damage to stock during handling
In many companies in the sector, materials and products may be damaged during movement, loading, unloading or handling in the course of normal operations. It is worth reviewing whether the policy covers this type of damage, particularly when sensitive or high-value materials are involved.
Liability coverages in insurance for life science companies
Alongside property, liability is another essential pillar. A standard public liability cover is not sufficient: insurance for life science companies must pay particular attention to products liability and other extensions related to recall, contamination, financial loss and clinical trials.
1. Products and completed operations liability
This is one of the most sensitive coverages in the sector. Products liability responds to third-party claims where the damage arises from a product already delivered or a completed service. Coverage is linked to defects originating during the manufacturing process, from conception through to delivery, including errors in instructions, labelling or the mistaken delivery of one product for another.
In the life science sector, this is particularly relevant for medicines, biological products, medical devices, products manufactured for third parties and components or substances incorporated into finished products.
2. Policy period and retroactive date on a claims-made basis
In liability insurance for this sector, the policy period is especially important. Many claims do not arise immediately: significant time may elapse between the manufacture, distribution, research or use of a product and the emergence of a loss, a safety alert or a formal claim.
It is worth reviewing whether the policy operates on a claims-made basis, what retroactive date it provides and whether there are coverage gaps for past unknown events at the time of inception. A broad retroactive date can be decisive in avoiding gaps in protection.
3. Combination and blending
When the insured’s product or component is incorporated into another good, the loss may not be limited to the defective product itself. Combination and blending extensions cover economic loss arising from the incorporation of the defective product into another good. This coverage is particularly useful for manufacturers of APIs, excipients, components, critical packaging, devices or parts intended to be integrated into a final product.
4. Assembly and disassembly costs
If the defective product has already been incorporated into another good, replacing it may require dismantling, removing and reassembling complete components or systems. This extension can make a significant difference for manufacturers of components or materials integrated into third-party products.
5. Product recall
A product recall can have a very significant economic and reputational impact: not only because of the direct cost of the recall, but also due to the operational, logistical and communications management involved. It is worth analysing whether the liability programme includes adequate product recall coverage and under what conditions it responds.
6. Clinical trials
For any company with clinical activity, this is a central issue. Clinical trials generate specific exposure that does not always fit correctly within a general products liability policy. It is important to review how the main policy coordinates with specific clinical trial policies, what limits apply and what regulatory or contractual requirements must be met.
7. Accidental pollution and pure financial loss
Their relevance will depend on each company’s specific activity, but these are coverages that typically distinguish a standard policy from a genuinely tailored solution. Reviewing accidental pollution, pure financial loss and other liability extensions allows the programme to be better aligned with the company’s operational reality.
What should a company review when arranging insurance for life science companies?
Rather than simply asking whether they have insurance, a company in the sector should analyse whether it has a programme that is genuinely adapted to its exposure. In particular, it is worth reviewing:
- Whether the coverages include sensitive stock, R&D assets and perishable materials.
- Whether the policy protects against income loss resulting from delays or business interruption.
- Whether the products liability coverage is well designed for the type of activity and product being commercialised.
- Whether specific coverages exist for recall, contamination or clinical trials.
- Whether limits, sub-limits, deductibles and indemnity periods are consistent with the actual risk exposure.
- Whether the liability policy period includes sufficient retroactivity and correctly covers the claims-made model.
The true value of insurance for life science companies lies not only in having a policy in place, but in how well its coverages are adapted to the operational, regulatory and financial reality of each company.
Conclusion
Life science companies operate in an environment where a single incident can simultaneously affect assets, projects, revenues and third-party liability. For this reason, insurance for life science companies must be built with a technical and sector-specific approach, not from a standard industrial logic.
Reviewing property and liability coverages properly enables better protection of business continuity, the value of research and the ability to respond to complex claims.
How O. Brokers can helpAt O. Brokers we help companies review their insurance programme with a technical, sector-focused approach aligned with the reality of their business. In complex sectors such as life science, the value lies not only in arranging a policy, but in correctly structuring coverages, limits and protection priorities. Would you like to know more? Get in touch with us. |
Frequently asked questions about insurance programmes for life science companies
What do insurance programmes for life science companies include?
Insurance programmes for life science companies can include property coverages (deterioration of perishable goods, biological contamination, R&D assets, milestone payments, delay in commercialisation) and liability coverages (products liability, recall, clinical trials, combination and blending, pure financial loss). These are specific programmes adapted to the risks of the pharmaceutical, biotechnology and medical device sectors.
Does a biotechnology company need a specific insurance policy?
Yes. A biotechnology company typically faces risks that go beyond a standard policy, particularly when R&D activities involve sensitive materials, contractual milestone payments with third parties or product liability exposure. A generic policy may leave significant coverage gaps in these areas.
What is most important in the liability coverage of a life science company?
It is worth reviewing products and completed operations liability, the policy period (on a claims-made basis with a broad retroactive date), and extensions for product recall, accidental pollution, combination and blending, and clinical trials. These are the aspects that most differentiate a tailored solution from a generic policy.
What should a life science company review in its property policy?
It should analyse whether the policy covers sensitive stock, R&D assets, temperature or humidity deterioration, biological contamination, income loss and delays in commercialisation. It is also important to review specific sub-limits and the territorial scope of each coverage.
What is the difference between public liability and products liability in life science?
Public liability covers damage caused to third parties in the course of business operations (for example, at the company’s premises). Products liability responds to claims arising from products already delivered or completed work. In life science, this second coverage is especially critical because losses may emerge long after the product has been delivered.
What are milestone payments in insurance for life science companies?
Milestone payment coverages protect contractually agreed amounts with third parties — linked to the achievement of research milestones — in the event that a loss affects R&D assets and delays the project. This is particularly relevant for biotechnology or research companies working under licensing, collaboration or development agreements.
How does time to market affect the insurance programme of a life science company?
Delay in commercialisation is a financial risk specific to the sector. Some insurance programmes for life science companies include a specific coverage that protects the loss of gross profit or fixed expenses when physical damage delays the planned launch of a new product or the improvement of an existing one. This type of coverage is not present in standard property policies.
